<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87144">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01970683</url>
  </required_header>
  <id_info>
    <org_study_id>MMC-2013-132</org_study_id>
    <nct_id>NCT01970683</nct_id>
  </id_info>
  <brief_title>Probiotics and Recovery From Surgery</brief_title>
  <acronym>PROGRESS</acronym>
  <official_title>Effect of Perioperative Probiotics on Clinical Outcomes of Patients Undergoing Major Abdominal Operation in Community Settings.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic Health Initiatives</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic Health Initiatives</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate whether probiotics given just before and shortly after major
      abdominal operation improve outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perioperative probiotic intervention is associated with approximately 30% reduction of
      primary outcome measure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day postsurgical outcome including death, infection, readmission</measure>
    <time_frame>within 30 days after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Major Abdominal Operation</condition>
  <arm_group>
    <arm_group_label>VSL #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>probiotics given orally BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Near-identically appearing placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VSL #3 BID</intervention_name>
    <arm_group_label>VSL #3</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All elective major GI surgical patients

        Exclusion Criteria:

          -  â€¢ Current episode of acute pancreatitis as defined by clinician

               -  Active medication-induced immunosuppression including systemic corticosteroids,
                  chemotherapy within 4 weeks, immunomodulating agents with transplant indication,
                  biologicals for rheumatoid arthritis and inflammatory bowel disease. Topical
                  chemotherapy or corticosteroids, and chemotherapy applied during operation are
                  allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mercy Medical Center-Des Moines</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marsha White</last_name>
      <phone>515-247-2985</phone>
      <email>mwhite3@mercydesmoines.org</email>
    </contact>
    <contact_backup>
      <last_name>Matthew Andres</last_name>
      <phone>515-247-3985</phone>
      <email>DAndres2@mercydesmoines.org</email>
    </contact_backup>
    <investigator>
      <last_name>Lauren DP Allan, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Franko, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 26, 2016</lastchanged_date>
  <firstreceived_date>October 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic Health Initiatives</investigator_affiliation>
    <investigator_full_name>Jan Franko</investigator_full_name>
    <investigator_title>Surgical Oncologist</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
